Clinical Trial Update: A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial compares 24-week versus 48-week courses of peginterferon plus ribavirin in genotype-1 chronic hepatitis C patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Conditions: Chronic Hepatitis C, Genotype | Phase 4 | Status: COMPLETED